Elevated endothelin levels are associated with increased placental resistance

Area of Science:

• Perinatology
• Neonatology
• Vascular Biology

Background:

• Fetal growth restriction (FGR) is associated with adverse neonatal outcomes.
• Abnormal fetoplacental blood flow, indicated by altered flow velocity waveforms, is a common complication in FGR.
• Endothelin-1,2 is a potent vasoconstrictor peptide implicated in vascular regulation.

Purpose of the Study:

• To quantify cord blood endothelin-1,2 concentrations in infants with FGR and abnormal flow velocity waveforms.
• To compare these levels with those in FGR infants with normal waveforms and appropriately grown infants.

Main Methods:

• Radioimmunoassay was used to measure endothelin-1,2 levels in cord blood samples.
• Study groups included 16 FGR infants with abnormal waveforms, 16 FGR infants with normal waveforms, and 44 controls.
• Clinical data on pregnancy complications and neonatal outcomes were collected.

Main Results:

• Mean endothelin-1,2 concentration was significantly elevated in FGR infants with abnormal waveforms (50.2 pg/ml) compared to FGR infants with normal waveforms (33.3 pg/ml) and controls (25.8 pg/ml).
• Elevated endothelin levels were also associated with oligohydramnios.
• A statistically significant difference (p < 0.05) was observed between groups.

Conclusions:

• Cord blood endothelin-1,2 concentrations are elevated in FGR infants presenting with abnormal flow velocity waveforms.
• Endothelin-1,2 may play a crucial role in the pathophysiology of increased fetoplacental vascular resistance in FGR.
• Further research is warranted to explore therapeutic interventions targeting the endothelin pathway.